Kirichenko Tatiana V, Sobenin Igor A, Markina Yuliya V, Gerasimova Elena V, Grechko Andrey V, Kashirskikh Dmitry A, Romanenko Elena B, Wu Wei-Kai, Orekhov Alexander N
Laboratory of Infection Pathology and Molecular Microecology, Institute of Human Morphology, 117418 Moscow, Russia.
Laboratory of Medical Genetics, National Medical Research Center of Cardiology, 121552 Moscow, Russia.
Biology (Basel). 2020 Apr 22;9(4):83. doi: 10.3390/biology9040083.
Chronic obstructive pulmonary disease (COPD) is a multifactorial disease, in which systemic inflammation plays a key role. This 6-month randomized double-blinded placebo-controlled study evaluates the possible effect of natural preparation Inflaminat on clinical symptoms of COPD, indicators of respiratory function, and exacerbation frequency in 60 patients with moderate severity of COPD. Inflaminat is a combination of natural ingredients black elder ( L.) berries, violet ( L.) herb, and calendula ( L.) flowers. The preparation has been previously demonstrated to possess anticytokine and anti-inflammatory effects in experimental studies. In present study, COPD dynamics were evaluated by means of BCSS (Breathlessness, Cough, and Sputum Scale) and spirometry tests. It was shown that 6-months Inflaminat administration led to significant decrease of BCSS points from 3.0 ± 0.6 to 1.9 ± 0.7, ( = 0.002) as well as significant increase of FEV1 from 66 ± 18% to 73 ± 17%, ( = 0.042); there were no beneficial dynamics in placebo group. Side effects associated with preparation administration were not identified. The results of the study suggest that Inflaminat may be employed in treatment of patients with moderate severity of COPD, since it has a positive effect on COPD symptoms according BCSS and indicators of respiratory function FEV1.
慢性阻塞性肺疾病(COPD)是一种多因素疾病,其中全身炎症起关键作用。这项为期6个月的随机双盲安慰剂对照研究评估了天然制剂Inflaminat对60例中度COPD患者的COPD临床症状、呼吸功能指标和急性加重频率的可能影响。Inflaminat是天然成分黑接骨木浆果、紫罗兰草药和金盏花花的组合。该制剂先前已在实验研究中证明具有抗细胞因子和抗炎作用。在本研究中,通过BCSS(呼吸急促、咳嗽和痰液量表)和肺活量测定试验评估COPD的动态变化。结果表明,服用6个月的Inflaminat导致BCSS评分从3.0±0.6显著降至1.9±0.7,(P = 0.002),同时FEV1从66±18%显著增加至73±17%,(P = 0.042);安慰剂组没有有益的变化。未发现与制剂给药相关的副作用。研究结果表明,Inflaminat可用于治疗中度COPD患者,因为它对根据BCSS的COPD症状和呼吸功能指标FEV1有积极作用。